Alnylam Pharmaceuticals, Inc. Form 4 Filings

ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt reported a compensation-related stock option grant. He received options to buy 4,393 shares of common stock at an exercise price of $295.63 per share. The options vest in three equal annual installments starting on the first anniversary of the grant date and expire in 2036. Following this grant, he holds 4,393 derivative securities directly.

ALNYLAM PHARMACEUTICALS, INC. director Charles Elliott Sigal reported new equity awards and updated holdings. He received 671 restricted stock units (RSUs), each representing a contingent right to one share of common stock, granted at no cash cost. These RSUs vest in full on the first anniversary of the grant date or upon an earlier qualifying retirement or resignation that occurs no more than 90 days before that anniversary. He was also granted a stock option for 1,441 shares of common stock at an exercise price of $298.48 per share, with the same vesting schedule and an expiration date in 2036. After these awards, he holds 1,446 common shares directly and 2,000 shares indirectly through Sigal Family Investments, LLC.

ALNYLAM PHARMACEUTICALS, INC. director Amy W. Schulman reported equity compensation awards rather than open-market trades. On May 20, 2026, she received 838 restricted stock units (RSUs), each representing one share of common stock, increasing her direct common stock holdings to 24,049 shares after the grant.

She was also granted stock options on 1,802 shares of common stock with a $298.48 exercise price, expiring on May 20, 2036. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or a qualifying retirement or resignation that occurs no more than 90 days before that anniversary.

Alnylam Pharmaceuticals director Colleen F. Reitan received new equity awards as part of her compensation. She was granted 671 restricted stock units, each representing one share of common stock, increasing her direct holdings to 1,446 common shares after the award.

She also received a stock option covering 1,441 common shares at an exercise price of $298.48 per share. Both the RSUs and the option vest in full on the earlier of the first anniversary of the grant date or her earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary.

Alnylam Pharmaceuticals director David E. I. Pyott reported new equity awards and updated holdings. He received 671 restricted stock units, each representing one share of common stock, increasing his direct holdings to 1,582 shares.

He was also granted stock options for 1,441 shares at an exercise price of $298.48 per share, vesting in full on the earlier of one year from grant or certain retirement or resignation conditions. Separately, a trust for which he is trustee holds 27,900 Alnylam shares, reported as indirect ownership.

ALNYLAM PHARMACEUTICALS, INC. director Peter N. Kellogg reported equity awards as part of his compensation. He received 671 restricted stock units, each representing one share of common stock, and 1,441 stock options with an exercise price of $298.48 per share.

The RSUs and options will each vest in full on the earlier of the first anniversary of the May 20, 2026 grant date or his earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary. After the RSU grant, he directly holds 1,446 common shares and 1,441 stock options.

ALNYLAM PHARMACEUTICALS, INC. director Margaret A. Hamburg reported equity awards consisting of common stock and stock options. She received 671 shares of common stock in the form of restricted stock units (RSUs) that each convert into one share when they vest. The RSUs will vest in full on the earlier of the first anniversary of the May 20, 2026 grant or an earlier retirement or resignation that occurs no more than 90 days before that date. She was also granted stock options for 1,441 shares of common stock at an exercise price of $298.4800 per share, with the same vesting schedule. After these awards, her directly held common stock position reported in this filing is 1,582 shares, and she holds options for 1,441 underlying shares.

ALNYLAM PHARMACEUTICALS, INC. director Olivier Brandicourt reported compensation-related equity awards, not open-market trades. He received 671 shares of common stock in the form of restricted stock units granted at no cash cost.

Brandicourt was also granted stock options for 1,441 shares of common stock at an exercise price of $298.48 per share. Both the RSUs and the options vest in full on the earlier of the first anniversary of the May 20, 2026 grant date or his earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary. Following these awards, he directly holds 1,446 common shares and 1,441 stock options.

ALNYLAM PHARMACEUTICALS, INC. director Dennis A. Ausiello reported equity awards and updated holdings. He received a grant of 671 restricted stock units, each representing one future share of common stock, which will vest in full on the first anniversary of the grant date or upon certain earlier retirement or resignation conditions. He was also granted stock options on 1,441 shares at an exercise price of $298.48 per share, with the option vesting on the same schedule. Following these awards, he holds 1,582 shares of common stock directly, 1,441 stock options directly, and 3,500 shares of common stock indirectly through a trust for which his spouse is trustee.

ALNYLAM PHARMACEUTICALS, INC. director Stuart A. Arbuckle received equity awards on May 20, 2026. He was granted 671 restricted stock units, each representing one share of common stock, and a stock option for 1,441 shares at an exercise price of $298.48 per share. Both the RSUs and the option vest in full on the earlier of the first anniversary of the grant date or an earlier retirement or resignation that occurs no more than 90 days before that anniversary. Following these awards, Arbuckle holds 671 common shares and a vested-over-time option covering 1,441 underlying shares.

ALNYLAM PHARMACEUTICALS director Amy W. Schulman exercised stock options to acquire 11,250 shares of common stock at $70.20 per share. These options were due to expire on June 3, 2026, and the exercise occurred on May 13, 2026. Following the transaction, she directly holds 23,211 common shares. The corresponding stock option position for these 11,250 shares has been fully exercised, with no remaining options from this grant shown in the filing.

Alnylam Pharmaceuticals’ Chief Human Resources Officer Melissa McLaughlin reported routine share sales tied to equity compensation taxes.

The Form 4 shows a total sale of 3,910 shares of common stock on April 2 and 6, 2026, executed automatically under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding on vested restricted stock units. After these transactions, she holds 9,443 shares directly. The filing notes the sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on December 16, 2025, indicating they were scheduled in advance rather than opportunistic trades.

ALNYLAM PHARMACEUTICALS, INC. EVP and Chief R&D officer Pushkal Garg reported open-market sales of 4,713 shares of common stock on March 4–5, 2026, at prices generally in the low-to-mid $320s per share, in multiple transactions.

The filing notes that some shares were automatically sold by the company to cover minimum statutory tax withholding when restricted stock units vested, and that certain transactions were executed under a Rule 10b5-1 trading plan adopted on November 20, 2025. Following these sales, Garg directly held 18,693 common shares, with additional indirect holdings reported through a managed account and a trust, the latter with a disclaimer of beneficial ownership.

Alnylam Pharmaceuticals Chief Executive Officer Yvonne Greenstreet reported automatic tax-related stock sales. On March 4, 2026, she sold a total of 2,933 shares of Alnylam common stock in a series of open-market transactions, at weighted average prices ranging from about $318 to $326 per share.

According to the disclosure, these sales were executed by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding tied to vesting restricted stock units. After these sales, Greenstreet directly owned 95,695 shares, and also held 407 shares indirectly through a managed account related to the company’s 401(k) matching program.

ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported selling 2,468 shares of common stock on March 4, 2026 in a series of open-market sales. Reported prices for these transactions include $319.03, $320.01, $320.81, $321.82, $323.01, $323.84, $324.88 and $325.67 per share.

According to a footnote, these shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations upon the vesting of restricted stock units. After these sales, Poulton directly owned 62,028 shares and indirectly held 57 shares of ALNY common stock through a managed account.

ALNYLAM PHARMACEUTICALS, INC. executive officer Tanguler Tolga reported automatic sales of common stock tied to equity compensation. On March 4, 2026, a total of 2,309 shares of common stock were sold in multiple open‑market transactions.

According to a footnote, these shares were sold by the company on the reporting person’s behalf under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding upon vesting of restricted stock units. After these sales, the reporting person directly held 34,297 common shares.

Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Joseph Fitzgerald reported open-market sales of company stock. On March 4–5, 2026, he sold a total of 1,291 shares of common stock in multiple transactions at prices generally in the low $320 range.

Footnotes state that some shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding on vested restricted stock units, and that the transactions were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025. After these sales, Fitzgerald directly owns 20,569 common shares and indirectly holds 537 shares through a managed account associated with the company’s 401(k) matching program.

ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported a mix of equity awards and stock sales. He received a stock option for 10,480 shares and 4,769 restricted stock units, both granted on March 2, 2026. The RSUs vest in three equal annual installments over three years, and the option vests over four years with 25% after one year and the balance quarterly thereafter, in each case subject to continued service. On the same date, he sold 2,206 shares of common stock in a series of open‑market transactions at weighted average prices in the low‑ to mid‑$320s per share, pursuant to a mandatory sell‑to‑cover provision to satisfy minimum tax withholding. Following these transactions, he directly held 64,273 common shares and indirectly held 57 shares through a managed account.

ALNY’s EVP and Chief R&D officer Pushkal Garg reported a mix of stock sales and equity awards. On March 2, 2026, he received a stock option for 10,480 shares and 4,769 restricted stock units under Alnylam’s 2018 Stock Incentive Plan, with both awards vesting over time based on continued service.

On March 2 and 3, 2026, he conducted open-market sales totaling 3,492 common shares at prices generally in the $316–$332 range, some under a Rule 10b5-1 trading plan and some automatically sold to cover tax withholding on the equity awards. Footnotes also show 431 shares held via a 401(k) managed account and 250 shares held in a trust for which he disclaims beneficial ownership.

ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported a mix of stock sales and equity awards. On March 2, 2026, he received a grant of 8,105 stock options and 3,688 shares of common stock represented by restricted stock units that vest in thirds over three years, subject to continued service. The stock options vest over four years, with 25% after one year and the balance in quarterly installments.

Across March 2–3, 2026, he executed open‑market sales totaling 3,250 common shares, some under a mandatory sell‑to‑cover tax provision and under a Rule 10b5‑1 trading plan adopted on August 14, 2025. After these transactions, he directly held 21,860 common shares, 8,105 options, and indirectly held 537 shares through a managed account.

ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief commercial officer Tolga Tanguler reported a mix of equity awards and related share sales. On March 2, 2026, he received stock options for 10,480 shares and a grant of 4,769 shares of common stock represented by restricted stock units that vest over three years.

On the same date, a total of 1,598 shares of common stock were sold in multiple open-market transactions at reported weighted-average prices in the low $320s to low $330s per share. According to the disclosure, these sales were automatically executed under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations. Following these transactions, Tanguler directly owned 36,606 shares of Alnylam common stock.

ALNYLAM PHARMACEUTICALS, INC. executive Bryan Supran, EVP, CLO and Secretary, reported equity awards consisting of stock options and restricted stock units. He received stock options for 3,381 shares at an exercise price of $0.00 per share, and a grant of 1,539 shares of common stock represented by restricted stock units.

The RSUs vest over three years, with one third vesting on each of the first, second and third anniversaries of the grant date, conditioned on continued service. The stock options vest 25% on the first anniversary of the grant date, with the remainder vesting in equal quarterly installments until the fourth anniversary, also subject to continuous service.

ALNYLAM PHARMACEUTICALS, INC. reported multiple equity transactions for Chief Executive Officer Yvonne Greenstreet. She received a grant of 30,425 stock options and 110,746 stock price performance stock units, both at a price of $0.00 per share. She also acquired 13,844 shares of common stock, including restricted stock units under the 2018 Stock Incentive Plan that vest over three years and shares acquired through the company’s 401(k) matching program. On the same date, a total of 6,799 shares of common stock were sold in a series of market transactions at weighted average prices around $323–$333 per share, which the company indicates were automatically sold to cover minimum statutory tax withholding obligations on the awards. Following these transactions, she directly held 98,628 shares of common stock and maintained additional indirect ownership through a managed account, and the performance units may vest on December 31, 2029 depending on future stock price performance.

ALNYLAM PHARMACEUTICALS, INC. Chief Executive Officer Yvonne Greenstreet reported the vesting and conversion of 5,921 restricted stock units into an equal number of common shares on February 27, 2026. These RSUs were part of a 17,763-unit grant from February 27, 2023 that vests in three equal annual installments.

Following this derivative exercise, her directly held common stock increased to 91,583 shares. She also has 407 common shares held indirectly in a managed account. The transaction reflects equity compensation vesting, not an open-market purchase or sale.

ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported the vesting of restricted stock units that converted into common shares. On February 27, 2026, 1,908 restricted stock units were exercised at $0.00 and settled into 1,908 shares of common stock.

These RSUs were part of a 5,724‑unit grant awarded on February 27, 2023, which vested in three equal annual installments. The filing notes that this transaction represents the third and final tranche from that grant. Following the conversion, Poulton directly owned 61,710 shares of common stock, and an additional 57 shares were held indirectly through a managed account.

Alnylam Pharmaceuticals executive Tolga Tanguler acquired shares through equity compensation. On February 27, 2026, 1,666 restricted stock units were exercised at $0.00 per share and converted into 1,666 shares of common stock, increasing his directly held stake to 33,435 shares.

These RSUs were part of a 5,000-unit grant awarded on February 27, 2023 under the company’s Amended and Restated 2018 Stock Incentive Plan. The award vested in three equal annual installments, and this filing reflects the third and final tranche becoming fully vested and released.

ALNYLAM PHARMACEUTICALS, INC. executive vice president and Chief R&D officer Pushkal Garg reported both an equity award vesting and share sales. On February 27, 2026, 1,908 restricted stock units were converted into common shares at no cost as the final tranche of a February 27, 2023 grant vested. That same day, he sold a total of 4,627 shares of common stock in multiple open-market transactions at prices ranging from about $328.92 to $334.39 per share under a pre-established Rule 10b5-1 trading plan adopted on November 20, 2025. After these transactions, he directly held 22,129 common shares, with additional shares held indirectly in a managed account and in a trust where his spouse is co-trustee, and he disclaims beneficial ownership of the trust shares.

ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported an equity award of company common stock. He acquired 158 shares of common stock on February 23, 2026 at a stated price of $0.00 per share as a grant/award.

According to the footnotes, this grant reflects shares issued in recognition of 20 years of continuous employment under a program that provides stock with an aggregate value of $100,000 to each qualifying employee, net of minimum statutory tax withholding. After this award, his directly held common stock totals 21,422 shares.

The filing also reports 537 shares of common stock held indirectly in a managed account, reflecting shares acquired through the company’s 401(k) matching contribution program.

Garg Pushkal reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 6,821 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 24,848 shares.

Greenstreet Yvonne reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 21,167 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 85,662 shares.

Tanguler Tolga reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 5,959 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 31,769 shares.

Fitzgerald Kevin Joseph reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 8,000 shares at a weighted average price of $321.24 per share. Following the reported transactions, holdings were 21,264 shares.

Poulton Jeffrey V. reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 6,821 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 59,802 shares.

Alnylam Pharmaceuticals executive Pushkal Garg, EVP Chief R&D, reported equity award vesting and related tax sales. On January 11, 2026, he received 3,800 shares of common stock upon vesting of 40% of a performance-based stock unit granted on March 1, 2024. The award vested after Alnylam publicly reported $2.5 billion in annual net product revenue under GAAP, as determined by the board’s People, Culture and Compensation Committee.

On January 12, 2026, multiple small blocks of common stock were automatically sold by the company on his behalf to cover minimum statutory tax withholding obligations tied to this award. Following these transactions, Garg directly held 22,511 common shares, plus 431 shares held indirectly by a managed account and 250 shares held in a trust where his spouse is co‑trustee; he disclaims beneficial ownership of the trust shares.

Alnylam Pharmaceuticals Chief Executive Officer and director Yvonne Greenstreet reported equity awards and related share sales. On January 11, 2026, she acquired 19,003 shares of common stock at $0.0 upon vesting of 40% of a performance-based stock unit granted on March 1, 2024, after the company publicly reported $2.5 billion in annual net product revenue under GAAP, as determined by the board’s People, Culture and Compensation Committee.

On January 12, 2026, the company automatically sold multiple small blocks of Alnylam common stock on her behalf, coded as "S" transactions, pursuant to a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding. These sales occurred at weighted average prices ranging from about $353.53 to $377.82 per share. After the reported transactions, she beneficially owned 78,411 shares directly and 407 shares indirectly through a managed account.

Alnylam Pharmaceuticals executive Jeffrey V. Poulton, EVP and Chief Financial Officer, reported equity award vesting and related share sales. On January 11, 2026, he received 6,193 shares of common stock at $0.0 upon vesting of 40% of a performance-based stock unit granted on March 1, 2024, after the company reported $2.5 billion in annual net product revenue under GAAP. On January 12, 2026, the company automatically sold multiple small blocks of Poulton’s shares, coded as sales, under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding, at weighted average prices described in ranges from $353.53 to $374.89. Following these transactions, Poulton directly held 57,465 Alnylam shares and indirectly held 57 shares through a managed account, and the footnotes note additional shares acquired via the issuer’s 401(k) matching contribution program.

Alnylam Pharmaceuticals executive Tolga Tanguler, EVP and Chief Commercial Officer, reported equity compensation activity and related tax sales. On January 11, 2026, he received 3,800 shares of common stock upon vesting of 40% of a performance-based stock unit granted on March 1, 2024, after the company publicly reported $2.5 billion in annual net product revenue under GAAP, as determined by the board’s People, Culture and Compensation Committee.

On January 12, 2026, the company automatically sold multiple small blocks of Tanguler’s shares pursuant to a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations, at weighted average prices across a range of transaction prices. Following these transactions, Tanguler directly beneficially owned 29,728 shares of Alnylam common stock.

Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Fitzgerald reported multiple equity transactions in the company’s common stock. On January 11, 2026, he received 3,800 shares at $0.0 per share upon vesting of a performance-based stock unit grant tied to the company publicly reporting $2.5 billion in annual net product revenue under GAAP, as determined by the board’s People, Culture and Compensation Committee.

On January 12, 2026, shares were automatically sold on his behalf under a mandatory sell-to-cover provision to satisfy minimum tax withholding, including blocks such as 39 shares at $353.95. On January 13, 2026, he executed additional open-market sales under a Rule 10b5-1(c) trading plan adopted on August 14, 2025, including 197 shares at $367.52 and 562 shares at $368.76. After these transactions, he held 21,264 shares directly and 537 shares indirectly through a managed account.

Alnylam Pharmaceuticals director Stuart A. Arbuckle reported receiving a stock option award for 3,279 shares of the company’s common stock. The option, granted on January 5, 2026, has an exercise price of $397.83 per share and is structured as a right to buy shares in the future.

According to the filing, the option will vest in three equal installments, with one third of the shares vesting on each of the first, second and third anniversaries of the grant date. Following this grant, Arbuckle beneficially owns 3,279 stock options directly.

Alnylam Pharmaceuticals executive Kevin Fitzgerald, CSO & EVP, Head of Research, reported an insider transaction in ALNY common stock. On 11/17/2025, he exercised a stock option for 8,161 shares at an exercise price of $119.13 per share and acquired the underlying common stock.

That same day, he reported multiple open-market sales of ALNY common stock in separate small lots, including 8,168 shares at $449 per share and additional sales at weighted average prices spanning from $451.41 to $463.46 per share, each based on multiple individual trades. After these transactions, he reported beneficial ownership of 24,999 shares directly, 537 shares indirectly through a managed account, and 839 derivative securities remaining from the option award. The filing notes that these trades were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025.

Alnylam Pharmaceuticals (ALNY) officer Bryan Supran reported acquiring 13,026 shares of common stock via a restricted stock unit (RSU) grant on 10/01/2025. Each RSU represents the right to receive one share. The RSUs vest over three years, with one third vesting on each of the first, second, and third anniversaries of the grant date, contingent on continued service.

Following the reported transaction, 13,026 shares were beneficially owned on a direct basis.

Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals (ALNY), reported equity changes tied to performance-based stock units (PSUs) that vested following corporate milestones. On 10/01/2025 the reporting person received 3,108 shares from a 2/24/2021 PSU tranche and 4,644 shares from a 3/01/2024 PSU tranche after the issuer publicly reported initiation of a Phase 3 clinical study in a prevalent indication, as determined by the People, Culture and Compensation Committee.

The company automatically sold 3,821 shares on 10/02/2025 under a mandatory sell-to-cover provision to satisfy statutory tax withholding, at weighted-average prices ranging roughly from $446.19 to $456.09 across multiple transactions. After these transactions the reporting person beneficially owned 54,052 shares directly and 57 shares indirectly via a managed account; 57 additional shares were acquired under the issuer 401(k) matching program.

Alnylam Pharmaceuticals (ALNY) CEO Yvonne Greenstreet reported PSU-related share activity. On 10/01/2025, she acquired 3,860 and 14,252 shares at $0 upon PSU vesting tied to the initiation of a Phase 3 clinical study, as determined by the PC&C Committee. On 10/02/2025, the Company executed sell-to-cover transactions to satisfy tax withholding, with multiple weighted-average sales ranging from $446.53 to $457.64. Following these transactions, she held 65,409 shares directly and 407 shares indirectly by a managed account.

Alnylam Pharmaceuticals (ALNY) executive Tolga Tanguler, EVP and Chief Commercial Officer, reported equity activity on a Form 4. On 10/01/2025, 2,851 common shares were acquired at $0.00 upon vesting of performance-based stock units tied to the initiation of a Phase 3 clinical study, as determined by the Board’s People, Culture and Compensation Committee.

On 10/02/2025, shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy tax withholding, executed in multiple trades with weighted average prices ranging from $446.19 to $457.64. Following these transactions, the reporting person beneficially owned 27,438 shares directly.

Alnylam Pharmaceuticals (ALNY) EVP Chief R&D Pushkal Garg reported PSU vesting and related share sales. On 10/01/2025, he acquired 3,108 and 2,851 common shares at $0.00 upon vesting tied to the company publicly reporting the initiation of Phase 3 clinical studies, as determined by the Board’s PC&C Committee.

On 10/02/2025, shares were sold automatically to cover taxes from the PSU settlements at disclosed weighted average prices by tranche; additional sales on 10/03/2025 were made under a Rule 10b5‑1(c) trading plan adopted on 09/11/2024. After these transactions, direct holdings were 20,221 shares, with 431 held via a managed account and 250 held in a trust.